首页> 美国卫生研究院文献>Oncotarget >Predictors of surgical outcomes and survival in rectal cancer patients undergoing laparoscopic total mesorectal excision after neoadjuvant chemoradiation therapy: the interest of pelvimetry and restaging magnetic resonance imaging studies
【2h】

Predictors of surgical outcomes and survival in rectal cancer patients undergoing laparoscopic total mesorectal excision after neoadjuvant chemoradiation therapy: the interest of pelvimetry and restaging magnetic resonance imaging studies

机译:新辅助化学放疗后接受腹腔镜全直肠系膜切除术的直肠癌患者手术结局和生存的预测指标:骨密度测定法和再分期磁共振成像研究的兴趣

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundLocally advanced rectal cancer (LARC) requires a multimodal therapy tailored to the patient and tumor characteristics. Pretreatment magnetic resonance imaging (MRI) is necessary to stage the primary tumor, while restaging MRI, which is not systematically performed, may be of interest to identify poor responders to neoadjuvant chemoradiation therapy (NCRT), and redefine therapeutic approach. The EuMaRCS study group aimed to investigate the role and accuracy of pretreatment (including pelvimetry) and restaging MRIs in predicting surgical difficulties and surgical outcomes in LARC therapy.
机译:背景局部晚期直肠癌(LARC)需要针对患者和肿瘤特征量身定制的多模式疗法。预处理磁共振成像(MRI)对于分期原发性肿瘤是必要的,而重新分期MRI(这不是系统性进行的)可能对于识别对新辅助化学放疗(NCRT)的不良反应以及重新定义治疗方法感兴趣。 EuMaRCS研究小组旨在研究预处理(包括骨密度测定法)和再分期MRI在预测LARC治疗中的手术困难和手术结果方面的作用和准确性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号